Is it Time for Reporting Guidelines for Calibration Methods? Scott B. Cantor Commentary 17 September 2012 Pages: 529 - 531
Calibration Methods Used in Cancer Simulation Models and Suggested Reporting Guidelines Natasha K. StoutAmy B. KnudsenG. Scott Gazelle Review Article 17 September 2012 Pages: 533 - 545
Societal and Patient Burden of Fibromyalgia Syndrome Lieven AnnemansKatell Le LayCharles Taïeb Review Article 17 September 2012 Pages: 547 - 559
Economic Evaluations in the EURONHEED Florencia HutterFernando Antoñanzas Review Article 17 September 2012 Pages: 561 - 570
Costs of Illness in a Russian Cohort of Patients with Parkinson’s Disease Yaroslav WinterSonja von CampenhausenAlla Guekht Original Research Article 17 September 2012 Pages: 571 - 584
Cost Effectiveness of Fondaparinux in Non-ST-Elevation Acute Coronary Syndrome Jaime Latour-PerezEva de-Miguel-Balsa Original Research Article 17 September 2012 Pages: 585 - 595
Cost-Effectiveness Analysis of Capecitabine Compared with Bolus 5-Fluorouracil/l-Leucovorin for the Adjuvant Treatment of Colon Cancer in Japan Takeru ShiroiwaTakashi FukudaKiichiro Tsutani Original Research Article 17 September 2012 Pages: 597 - 608
Cost Utility of Adalimumab versus Infliximab Maintenance Therapies in the United States for Moderately to Severely Active Crohn’s Disease Andrew P. YuScott JohnsonParvez M. Mulani Original Research Article 17 September 2012 Pages: 609 - 621